Abstract：Objective: To investigate the effect of hepatic arterial cathetering chemoembolization on patients with unresectable intrahepatic cholangiocarcinoma. Methods: The clinical data of 73 patients with unresectable intrahepatic cholangiocarcinoma from June 2012 to December 2014 were retrospectively analyzed. The patients were treated with hepatic artery cathetering chemoembolization or hepatic artery perfusion chemoembolization. The curative effect, objective response rate, clinical benefit rate, survival time and adverse reaction were compared between two groups. Results: In hepatic artery cathetering chemoembolization group, complete response(CR) was 5 cases, partial response(PR) was 15 cases, stable disease(SD) was 9 cases, and progressive disease(PD) was 5 cases, the objective response rate was 58.8% and clinical benefit rate was 85.3%. In hepatic artery perfusion chemoembolization group, CR was 3 cases, PR was 12 cases, SD was 10 cases, and PD was 14 cases, the objective response rate was 38.5% and clinical benefit rate was 64.1%. There was significant difference of clinical benefit rate between the two groups(P<0.05). There was no significant difference in adverse reaction between the two groups(P＞0.05). The median survival time was 19.04 months and 13.03 months respectively, and the difference was statistically significant between the groups(P<0.05). Conclusion: Patients with unresectable intrahepatic cholangiocarcinoma can benefit from hepatic artery cathetering chemoembolization, especially in the clinical benefit rate and survival time.
张 浩，向 华，张永琎，张智明，刘觉仕，方志勇，王 庆. 肝动脉置管化疗栓塞治疗不可切除胆管细胞型肝癌的疗效观察[J]. 中国临床医学影像杂志, 2017, 28(4): 286-290.
ZHANG Hao, XIANG Hua, ZHANG Yong-jin, ZHANG Zhi-ming, LIU Jue-shi, FANG Zhi-yong, WANG Qing. Effect of hepatic arterial cathetering chemoembolization in the treatment of unresectable intrahepatic cholangiocarcinoma. JOURNAL OF CHINA MEDICAL IMAGING, 2017, 28(4): 286-290.
[1]Simo KA, Halpin LE, McBrier NM, et al. Multimodality treatment of intrahepatic cholangiocarcinoma: a review[J]. J Surg Oncol, 2016, 113(1): 62-83.
[2]Brandi G, Venturi M, Pantaleo MA, et al. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center[J]. Dig Liver Dis, 2016, 48(3): 231-241.
[3]Fan B, Malato Y, Calvisi DF, et al. Cholangiocarcinomas can originate from hepatocytes in mice[J]. J Clin Invest, 2012, 122(8): 2911-2915.
[4]汤钊猷. 现代肿瘤学[M]. 2版. 上海：复旦大学出版社，2000：745.
[5]Lencioni R, Llovet JM. Modified RECIST(mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60．
[6]Chinese Chapter of International Hepato-Pancreato-Biliary Association, Hepatic Sugery Group, Chinese Society of Surgery, Chinese Medical Association. Diagnosis and treatment of cholangiocarcinoma: sugical expert consensus[J]. J Clin Hepatol, 2015, 31(1): 12-16.
[7]陈漪，王志明，叶胜龙，等. CA19-9对肝细胞癌和胆管细胞癌的诊断价值[J]． 中华肝脏病杂志，2006，14（4）：299-300．
[8]Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study[J]. Clin Gastroenterol Hepatol, 2007, 5(10): 1221－1228.
[9]Fava G, Marzioni M, Benedetti A, et al. Molecular pathology of biliary tract cancers[J]. Cancer Lett, 2007, 250(2): 155-167.
[10]Ben-Menachem T. Risk factors for cholangiocarcinoma[J]． Eur J Gastroenterol Hepatol, 2007, 19(8): 615－617.
[11]黄元哲，杨新伟，杨家和. 肝内胆管细胞癌的治疗进展[J]． 肝胆外科杂志，2014，22（1）：73-76.
[12]李绍林，张雪林，陈燕萍，等. 肝内周围型胆管细胞癌CT和MRI诊断及病理基础研究[J]. 中华放射学杂志，2004，38（10）：1072-1074．
[13]Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution[J]． J Vasc Interv Radiol, 2005, 16(3): 353-361.
[14]Herber S, Otto G, Schneider J, et al. Transarterial chemoembolization(TACE) for inoperable intrahepatic cholangiocarcinoma[J]． Cardiovasc Intervent Radiol, 2007, 30(6): 1156-1165.
[15]Lassen U, Jensen LH, Sorensen M, et al. A Phase Ⅰ-Ⅱ dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas[J]. Acta Oncol, 2011, 50(3): 448-454.
[16]Leong E, Chen WW, Ng E, et al. Outcomes from combined chemoradiotherapy in unresectable and locally advanced resected cholangiocarcinoma[J]. J Gastrointest Cancer, 2012, 43(1): 50-55.
[17]Weigt J, Malfertheiner P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. Expert Rev Gastroenterol Hepatol, 2010, 4(4): 395-397.
[18]田薇薇，李苏宜. 5-氟尿嘧啶持续滴定联合小剂量顺铂治疗晚期肿瘤的机理和应用进展[J]. 临床肿瘤杂志，2001，6（3）：93-95.
[19]Ducreux M, Van Cutsem E, Van Laethem JL, et al. A randomised phase Ⅱ trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40 955 EORTC trial[J]. Eur J Cancer, 2005, 41(3): 398-403.
[20]Wada H, Nagano H, Dono K, et al. Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin(FAP): two cases report[J]. Gan To Kagaku Ryoho, 2004, 31(11): 1711-1713.
[21]Kobayashi K, Tsuji A, Morita S, et al. A phase Ⅱ study of LFP therapy(5-FU(5-fluorourasil) continuous infusion(CVI) and Low-dose consecutive(Cisplatin) CDDP) in advanced biliary tract carcinoma[J]. BMC Cancer, 2006, 6: 121.
